Wapnick Pamela 4
4 · Metagenomi Therapeutics, Inc. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Metagenomi (MGX) CFO Pamela Wapnick Sells 1,581 Shares
What Happened Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, sold 1,581 shares of common stock on 2026-03-05 at $1.60 per share, generating approximately $2,530 in proceeds. According to the filing, this sale was an automatic disposition to satisfy tax-withholding obligations on restricted stock units that vested and was not a volitional market trade by the reporting person.
Key Details
- Transaction date: 2026-03-05; Price: $1.60 per share; Shares sold: 1,581; Proceeds ≈ $2,530.
- Filing date: 2026-03-09 (filed within the Form 4 reporting window — timely).
- Reason/footnote: Shares were automatically sold to satisfy tax withholding for RSUs granted on 2024-04-01 (Footnote F1); not a discretionary sale.
- Shares owned after the transaction: not specified in the provided filing extract.
Context Automatic sales to cover tax withholding on vesting awards are common and generally not interpreted as a directional signal about an insider’s view of the stock. This was not a purchase or exercise; it was a withholding-related sale of vested RSU shares.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-05$1.60/sh−1,581$2,530→ 187,375 total
Footnotes (1)
- [F1]These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.